Biodesix enters its third-quarter report with a story that has rarely looked better on the diagnostics side and rarely looked thinner on the pharma side. Test volume growth has accelerated for three straight quarters, climbing from 23% to 29% to 38%, and management credits a March validation study showing its Notify CDT test can flag cancer in nodules as small as 4mm. The open question for the November 5 release, due after the close, is whether that momentum is strong enough to make the company's reaffirmed full-year outlook look conservative, or whether the deceleration built into the second half is real.
The Street is looking for a loss of $0.74 per share on revenue of $27.3 million. That top line would represent roughly 25% growth from the $21.8 million posted a year ago, which is solid but well below the roughly 34% total revenue growth Biodesix delivered last quarter. It is also only a modest step up from the second quarter's $26.9 million. The per-share loss estimate would mark a meaningful improvement from the $1.16 loss a year earlier, though it is slightly wider than last quarter's $0.71. The whisper number of a $0.65 loss sits noticeably better than consensus, suggesting the more engaged crowd expects the cost discipline seen last quarter, when operating expenses rose just 7%, to carry through.
Management reaffirmed its 2026 revenue range of $108 million to $114 million after raising it on the first-quarter call. Consensus of about $111.1 million sits squarely at the midpoint, so analysts are neither stretching nor hedging. The tension is in the math: the guide implies second-half growth of roughly 16% to 22%, a sharp slowdown from the first half, partly because last year's second half included about $1 million in back-pay collections. A third quarter growing at 25% would already run ahead of that implied pace, which is why a clean beat here could revive talk of another raise, while a print near the low end of expectations would suggest management's caution was warranted.
The operating details matter more than the headline. Diagnostic testing revenue grew 42% last quarter, and primary care volume more than doubled, so the first test is whether the publication-driven ordering trend management described as durable keeps compounding. The second is Development Services, which fell to $1.5 million last quarter as contracted backlog slid for a fourth consecutive quarter to $8.5 million. Management pointed to lumpiness and a forming pharma pipeline after strong ASCO engagement; a stabilizing or rising backlog would validate that, while another decline would make the soft spot look structural. Sales headcount is the third swing factor. The company averaged about 104 reps, roughly two short of plan, and needs to reach around 120 to support the back half. With gross margin already at 82% and the CFO signaling limited room for further expansion, earnings improvement must come from volume and expense leverage, not pricing or mix.
The market has been ambivalent. Shares are up less than 1% since the last report, roughly matching a flat S&P 500, but that masks a round trip: the stock ran as high as about $32 before retreating to near $22, closer to the bottom of its post-earnings range than the top, though still comfortably above its 200-day moving average near $18.38. Sentiment has edged up only slightly, to 38.1% bullish from 36.2%, indicating cautious optimism rather than euphoria. Pending catalysts, including a possible CHEST guideline update that could include blood-based biomarkers for the first time in more than a decade and a planned November pipeline update, give the stock reasons to rerate beyond the quarter itself.
Ultimately, this report hinges on whether diagnostic volume growth stays in the high 30s while the pharma business stops shrinking. If both happen, the reaffirmed guide starts to look like a floor. If volume cools toward the implied second-half pace, the stock's retreat from its highs may prove justified.